Braveheart Bio is a late clinical-stage biopharmaceutical company developing novel therapeutics for hypertrophic cardiomyopathy (HCM) and related cardiac conditions. Its lead candidate, BHB-1893, is a selective cardiac myosin inhibitor (licensed as HRS-1893 from Hengrui Pharma) designed to reduce excessive heart-muscle contraction and improve…

Ark Biopharmaceutical (爱科百发, Ark Biosciences) is a Shanghai-based clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for respiratory diseases and pediatric conditions.

ArriVent BioPharma (NASDAQ: AVBP) is a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines for the treatment of cancer.

Metsera is a clinical-stage biopharmaceutical company developing injectable and oral therapies for obesity and metabolic diseases, backed by GV and the SoftBank Vision Fund. As of this enrichment pass its corporate domain (metsera.com) issues a 301 redirect to pfizer.com, consistent with Metsera's acquisition by Pfizer.

Granata Bio is a reproductive-health biopharmaceutical company founded in 2018 and headquartered in the United States, focused on expanding access to fertility and IVF therapeutics across North America.

Abbisko Therapeutics (上海和誉生物医药科技有限公司) is a Shanghai-based clinical-stage biopharmaceutical company focused on the discovery and development of innovative small-molecule therapeutics, primarily in oncology. It was surfaced as a portfolio company of Qiming Venture Partners and added to the API Evangelist network as a stub.

ArriVent BioPharma is a clinical-stage biopharmaceutical company focused on the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with difficult-to-treat diseases, beginning with cancers.

Arresto Biosciences, Inc. was a privately-held, development-stage biotechnology company headquartered in Palo Alto, California, focused on medicines to treat fibrotic diseases and cancer by targeting enzymes involved in the synthesis of the extracellular matrix.

CREATE Medicines is a Cambridge, Massachusetts biopharmaceutical company developing in vivo CAR (chimeric antigen receptor) cell therapies using mRNA lipid-nanoparticle (mRNA-LNP) delivery.

Millennium Pharmaceuticals was a biopharmaceutical company based in Cambridge, Massachusetts, focused on oncology and inflammation, best known for developing the cancer drug Velcade (bortezomib).

Aer Therapeutics is a clinical-stage biopharmaceutical company based in the Research Triangle Park / Raleigh area of North Carolina, developing novel treatments for muco-obstructive lung diseases such as COPD, asthma, cystic fibrosis, and non-CF bronchiectasis. A spinout from Dr.

kechowpharma — Kechow Pharma (Shanghai Kezhou Pharmaceutical Co., Ltd.) is a clinical-stage biopharmaceutical company founded in 2014 and headquartered in Shanghai's Zhangjiang High-Tech Park.

Frontier Medicines is a clinical-stage biopharmaceutical company pioneering the discovery and development of small-molecule covalent drugs against disease-causing proteins long considered undruggable.

Chimerix, Inc. was a biopharmaceutical company headquartered in Durham, North Carolina, focused on developing medicines for serious and life-threatening diseases. It is best known for brincidofovir (TEMBEXA), an antiviral approved by the U.S.

Axcelius I/II is a biopharmaceutical company-creation vehicle backed by Canaan Partners, formed to found and incubate drug-development companies pursuing treatments for cancer, rare diseases, and neurodegenerative disorders.

Barinthus Biotherapeutics plc (Nasdaq: BRNS) is a clinical-stage biopharmaceutical company developing novel immunotherapies designed to guide and reprogram T cells to overcome autoimmunity, inflammatory disease, chronic viral infection, and cancer.

Georgiamune Inc. is a Gaithersburg, Maryland based biopharmaceutical company developing first-in-class immunotherapies that reprogram immune signaling pathways to rebalance the immune system and restore health across cancer and autoimmune diseases.

Civitas Therapeutics was a privately held biopharmaceutical company founded in 2009 (Chelsea/Cambridge, Massachusetts) that developed inhaled therapeutics using the proprietary ARCUS dry-powder pulmonary delivery platform.

Day One Biopharmaceuticals is a commercial-stage biopharmaceutical company developing and commercializing targeted therapies for people of all ages living with life-threatening diseases, with an initial focus on pediatric and rare cancers.

Antengene Corporation is a commercial-stage, R&D-driven global biopharmaceutical company focused on discovering, developing, and commercializing first-in-class and best-in-class therapies for the treatment of hematologic malignancies and solid tumors.